Oncopeptides Drops Another 37% as Downgrades Continue on Likely Cash Need

• (PLX AI) - Oncopeptides dropped another 37% today, adding to massive losses from Friday as more analysts cut the stock after the company withdrew Pepaxto from the U.S. market.
• • Cut to sell from buy at DNB
• • Cut to hold from buy at Carnegie
• • Price target cut to SEK 0.35 from SEK 12 at SEB (sell reiterated)
• • Investor confidence has evaporated, DNB said
• • Most likely the company will need to raise cash, which may prove to be a challenge: DNB